We are delighted to announce the publication of independent research conducted by MedImmune, which provides validation that the xB3 platform efficiently delivers antibodies across the blood-brain barrier at therapeutic doses. To learn more about the research published in the Journal of Cerebral Blood Flow and Metabolism, please visit: https://www.bioasis.us/bioasis-announces-publication-of-independent-validation-of-the-companys-xb3-platform-technology/